Mark Briggs - Welsh Blood Service
Mark Briggs is Head of Cell and Gene Therapy for the Welsh Blood Service and Head of Strategy for Research, Development and Innovation for the Velindre Cancer Centre, both divisions within the Velindre University NHS Trust. He is also Programme Lead for Advanced Therapies Wales and co-director of the Midland-Wales Advanced Therapy Treatment Centre (UKRI funded grant programme) both of which have a focus on equitable adoption and deployment of cell and gene therapies within the NHS.
Prior to moving to the public sector Mark spent more than 20 years within commercial Life Sciences R&D leading the application of enabling and disruptive technologies to drug discovery, development, safety testing. In his latter corporate years, he focussed upon the industrialisation of advanced therapies with a view to enabling safe and robust, turn-key production of both genetically and non-genetically modified cellular therapies.